Mohamad Dave Dimachkie1, Misty D Bechtel1, Hilary L Robertson1, Carrie Michel1, Eugene K Lee1, Debra K Sullivan2, Prabhakar Chalise3, J Brantley Thrasher1, William P Parker1, Andrew K Godwin4, Harsh B Pathak4, John DiGiovanni5, Nitin Shivappa6, James R Hébert6, Jill M Hamilton-Reeves7. 1. Department of Urology, University of Kansas Medical Center, Kansas City, KS. 2. Department of Dietetics & Nutrition, University of Kansas Medical Center, Kansas City, KS. 3. Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS. 4. Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS. 5. Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX. 6. Cancer Prevention and Control Program, University of South Carolina, Columbia, SC 29208; Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC; Connecting Health Innovations LLC, Columbia, SC. 7. Department of Urology, University of Kansas Medical Center, Kansas City, KS; Department of Dietetics & Nutrition, University of Kansas Medical Center, Kansas City, KS. Electronic address: jhamilton-reeves@kumc.edu.
Abstract
BACKGROUND: Several biologic mechanisms, including inflammation and immune changes, have been proposed to explain the role of obesity in prostate cancer (CaP) progression. Compared to men of a healthy weight, overweight and obese men are more likely to have CaP recurrence post-prostatectomy. Obesity is related to inflammation and immune dysregulation; thus, weight loss may be an avenue to reduce inflammation and reverse these immune processes. OBJECTIVES: This study explores the reversibility of the biological mechanisms through intentional weight loss using a comprehensive weight management program in men undergoing prostatectomy. Outcomes include blood and tissue biomarkers, microtumor environment gene expression, inflammation markers and Dietary Inflammatory Index (DII) scores. METHODS: Twenty overweight men undergoing prostatectomy participated in this study. Fifteen men chose the intervention and 5 men chose the nonintervention group. The intervention consisted of a comprehensive weight loss program prior to prostatectomy and a weight maintenance program following surgery. Prostate tissue samples were obtained from diagnostic biopsies before the intervention and prostatectomy samples after weight loss. Blood samples and diet records were collected at baseline, pre-surgery after weight loss and at study end after weight maintenance. Immunohistochemistry and NanoString analysis were used to analyze the tissue samples. Flow cytometry was used to assess circulating immune markers. Inflammation markers were measured using Luminex panels. RESULTS: The intervention group lost >5% body weight prior to surgery. DII scores improved during the weight loss intervention from baseline to pre-surgery (P = 0.002); and between group differences were significant (P = 0.02). DII scores were not associated with IL-6 nor hsCRP. In the intervention, CXCL12, CXCR7, and CXCR4 (C-X-C motif chemokine ligand/receptor) and Ki67 expression decreased in the prostate tissue from biopsy to surgery (P = 0.06), yet plasma CXCL12 increased during the same timeframe (P = 0.009). The downregulation of several genes (FDR<0.001) was observed in the intervention compared to the non-intervention. Changes in immune cells were not significant in either group. CONCLUSION: This feasibility study demonstrates that in overweight men with localized CaP, weight loss alters blood, and tissue biomarkers, as well as tumor gene expression. More research is needed to determine the biological and clinical significance of these findings.
BACKGROUND: Several biologic mechanisms, including inflammation and immune changes, have been proposed to explain the role of obesity in prostate cancer (CaP) progression. Compared to men of a healthy weight, overweight and obese men are more likely to have CaP recurrence post-prostatectomy. Obesity is related to inflammation and immune dysregulation; thus, weight loss may be an avenue to reduce inflammation and reverse these immune processes. OBJECTIVES: This study explores the reversibility of the biological mechanisms through intentional weight loss using a comprehensive weight management program in men undergoing prostatectomy. Outcomes include blood and tissue biomarkers, microtumor environment gene expression, inflammation markers and Dietary Inflammatory Index (DII) scores. METHODS: Twenty overweight men undergoing prostatectomy participated in this study. Fifteen men chose the intervention and 5 men chose the nonintervention group. The intervention consisted of a comprehensive weight loss program prior to prostatectomy and a weight maintenance program following surgery. Prostate tissue samples were obtained from diagnostic biopsies before the intervention and prostatectomy samples after weight loss. Blood samples and diet records were collected at baseline, pre-surgery after weight loss and at study end after weight maintenance. Immunohistochemistry and NanoString analysis were used to analyze the tissue samples. Flow cytometry was used to assess circulating immune markers. Inflammation markers were measured using Luminex panels. RESULTS: The intervention group lost >5% body weight prior to surgery. DII scores improved during the weight loss intervention from baseline to pre-surgery (P = 0.002); and between group differences were significant (P = 0.02). DII scores were not associated with IL-6 nor hsCRP. In the intervention, CXCL12, CXCR7, and CXCR4 (C-X-C motif chemokine ligand/receptor) and Ki67 expression decreased in the prostate tissue from biopsy to surgery (P = 0.06), yet plasma CXCL12 increased during the same timeframe (P = 0.009). The downregulation of several genes (FDR<0.001) was observed in the intervention compared to the non-intervention. Changes in immune cells were not significant in either group. CONCLUSION: This feasibility study demonstrates that in overweight men with localized CaP, weight loss alters blood, and tissue biomarkers, as well as tumor gene expression. More research is needed to determine the biological and clinical significance of these findings.
Authors: Xavier Michelet; Lydia Dyck; Andrew Hogan; Roisin M Loftus; Danielle Duquette; Kevin Wei; Semir Beyaz; Ali Tavakkoli; Cathriona Foley; Raymond Donnelly; Cliona O'Farrelly; Mathilde Raverdeau; Ashley Vernon; William Pettee; Donal O'Shea; Barbara S Nikolajczyk; Kingston H G Mills; Michael B Brenner; David Finlay; Lydia Lynch Journal: Nat Immunol Date: 2018-11-12 Impact factor: 25.606
Authors: Natasa Obermajer; Ravikumar Muthuswamy; Kunle Odunsi; Robert P Edwards; Pawel Kalinski Journal: Cancer Res Date: 2011-10-24 Impact factor: 12.701
Authors: Corinne E Joshu; Alison M Mondul; Andy Menke; Cari Meinhold; Misop Han; Elizabeth B Humphreys; Stephen J Freedland; Patrick C Walsh; Elizabeth A Platz Journal: Cancer Prev Res (Phila) Date: 2011-02-16
Authors: Tammy Ho; Leah Gerber; William J Aronson; Martha K Terris; Joseph C Presti; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: Eur Urol Date: 2012-08-20 Impact factor: 20.096
Authors: Daniel W Lin; Marian L Neuhouser; Jeannette M Schenk; Ilsa M Coleman; Sarah Hawley; David Gifford; Hau Hung; Beatrice S Knudsen; Peter S Nelson; Alan R Kristal Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-10 Impact factor: 4.254